WILMINGTON, N.C., Jul 27, 2010 (GlobeNewswire via COMTEX) -- TranS1 Inc. (TSON 2.43, +0.11, +4.74%), a pioneer in novel approaches to lumbar spine surgery, today announced the launch of the AxiaLIF(R) 2L+(TM)product line, an instrumentation and implant system for L4-S1 lumbar fusion. The AxiaLIF 2L+ system represents the next generation of the original AxiaLIF 2L system first launched in 2008. Since receiving FDA 510(k) clearance in January, 2010, AxiaLIF 2L+ has been available under a limited market release. It will now be made available to trained surgeons throughout the U.S. "Our new AxiaLIF 2L+ system further demonstrates TranS1's commitment to continuously advancing our proprietary AxiaLIF core technology. The L4-S1 region of the spine accounts for approximately 40% of all lumbar fusions yet existing surgical techniques are highly invasive for patients," stated Ken Reali, TranS1's President and COO. "Due to our unique access route to the spine, the AxiaLIF 2L+ is a less invasive procedure for patients. Further, our implant allows a surgeon to provide controlled distraction during the operation to precisely restore lost disc height." About TranS1 Inc. TranS1 is a medical device company focused on designing, developing and marketing products that implement its proprietary approach to treat degenerative conditions of the spine affecting the lower lumbar region. TranS1 currently markets the AxiaLIF family of products for single and multilevel lumbar fusion and the Vectre and Avatar posterior fixation systems for lumbar fixation supplemental to AxiaLIF fusion. TranS1 was founded in May 2000 and is headquartered in Wilmington, North Carolina. For more information, visit www.trans1.com.
CONTACT: TranS1 Inc. Investors: Joe Slattery, Chief Financial Officer 910-332-1700 Westwicke Partners Mark Klausner 443-213-0501 firstname.lastname@example.org